HotSpot Therapeutics leverages its Smart Allostery™ platform to discover and develop first-in-class allosteric therapies by identifying protein pockets termed 'natural hotspots'. The platform combines AI-enabled technologies with a large, diverse chemical library tailored to hotspots. The company is applying the platform across a wide array of disease-relevant and previously undrugged or poorly druggable targets. HotSpot intends to use the new funding to continue advancing the Smart Allostery™ platform and its existing pipeline. The company is led by CEO Jonathan Montagu and emphasizes capturing and drugging natural hotspots through its technology suite. Financially, HotSpot closed a $100M Series C, bringing total funding to $190M. HotSpot Therapeutics develops allosteric medicines by exploiting natural protein control mechanisms, using its SpotFinder™ platform to identify regulatory “hotspots” amenable to small-molecule discovery. The platform leverages advanced machine learning and 3D structure insights to uncover regulatory pockets, and the company has designed in-house DNA-encoded libraries (DELs) comprising millions of tailored molecules. A proprietary screening paradigm using custom protein constructs, phenotypic screens and biophysics assays is used to validate hotspot-targeted molecules. The company intends to use the proceeds from its recent financing to advance lead programs to the clinic, including protein kinase C (PKC‑theta) antagonists for Th2- and T‑reg-driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease. HotSpot also plans to accelerate its discovery-stage pipeline targeting genetically validated transcription factors and E3 ligases, including CBL‑B. Jonathan Montagu leads the company. HotSpot Therapeutics uses its proprietary SpotFinder™ technology to systematically identify regulatory "hotspots"—a family of allosteric sites used by nature to regulate protein function. The company applies bespoke chemistry to develop first‑in‑class allosteric medicines for serious autoimmune and metabolic diseases. Its pipeline includes lead allosteric inhibitors targeting PKC‑theta for autoimmune indications and S6 kinase, an immunometabolic enzyme relevant to hepatic insulin sensitivity and mitochondrial function for NASH and metabolic diseases. HotSpot has identified over 100 regulatory hotspots across multiple proteins and pathways. Financially, the company completed a $45M Series A financing. The company was founded in 2017 and is based in Cambridge, Mass.

Total raised

$210M

Funding rounds

3

Latest round

Series C

Latest activity

Nov 2021